Bayer’s not breaking up. At least not yet

Off Biotech, biotechnology, Business, drug development, drug prices, drug pricing, finance, Health, Human Health, Life Sciences, Medicine, Pharma, research, Science and Research, The Readout

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, everyone. Damian here with news of another biotech megaround, the potential next big thing from Novo Nordisk, and an anti-aging dispute involving dogs.

Read the rest…

Read Original Article: Bayer’s not breaking up. At least not yet »

About The Author